Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19

dc.contributor.authorEldanasory, Omar Abdelhay
dc.contributor.authorEljaaly, Khalid
dc.contributor.authorMemish, Ziad A.
dc.contributor.authorAl-Tawfiq, Jaffar A.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2020-09-09T20:29:35Z
dc.date.available2020-09-09T20:29:35Z
dc.date.issued2020-09-03
dc.description.abstractHistamine initiates abnormal immune response leading to cytokine storm and multi-organs failure. Thus, the use of antihistaminic medications could result in a significant immune modulation which may help in the treatment of cytokine storm of COVID-19. Future studies could compare H2R antagonists with those of steroid therapy in addition to the effect of combination therapy in relation to standard therapy.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationEldanasory, O. A., Eljaaly, K., Memish, Z. A., & Al-Tawfiq, J. A. (2020). Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19. Travel Medicine and Infectious Disease. https://doi.org/10.1016/j.tmaid.2020.101874en_US
dc.identifier.issn1477-8939en_US
dc.identifier.urihttps://hdl.handle.net/1805/23790
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.relation.isversionof10.1016/j.tmaid.2020.101874en_US
dc.relation.journalTravel Medicine and Infectious Diseaseen_US
dc.rightsIUPUI Open Access Policyen_US
dc.sourceAuthoren_US
dc.subjectCOVID-19en_US
dc.subjectHistamineen_US
dc.subjectCytokines Stormen_US
dc.subjectAntihistaminesen_US
dc.subjectTreatmenten_US
dc.titleHistamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Eldanasory2020Histamine.pdf
Size:
104.03 KB
Format:
Adobe Portable Document Format
Description:
Article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: